Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: NextCure, Inc.

Market Cap 7.08M 6.11M 5.62M 5.29M 9.93M 668M 10.01M 66.54M 25.91M 328M 26.57M 26M 1.13B P/E 2026 *
-0.27x
P/E 2027 * -0.24x
Enterprise Value 7.08M 6.11M 5.62M 5.29M 9.93M 668M 10.01M 66.54M 25.91M 328M 26.57M 26M 1.13B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
85.16%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: NextCure, Inc.

1 day+5.61%
1 week-7.17%
Current month-66.61%
1 month-77.62%
3 months-83.20%
6 months-80.30%
Current year-85.41%
1 week 1.78
Extreme 1.78
2.5
1 month 1.78
Extreme 1.78
10.71
Current year 1.78
Extreme 1.78
14.65
1 year 1.78
Extreme 1.78
15.74
3 years 1.78
Extreme 1.78
30.84
5 years 1.78
Extreme 1.78
110.16
10 years 1.78
Extreme 1.78
1,308
Manager TitleAgeSince
Chief Executive Officer 65 01/12/2015
Director of Finance/CFO 63 01/01/2018
Chief Tech/Sci/R&D Officer 54 -
Director TitleAgeSince
Director/Board Member 65 01/12/2015
Director/Board Member 71 01/12/2015
Chairman 78 01/12/2015
Date Insider Type Main position Quantity % Market Cap.
01-30Free

Executive/Senior Manager

8,270 0.3090%
01-30Free

General Counsel

8,270 0.3090%
01-30Free

Chief Technology Officer

14,670 0.5482%
Change 5-day change 1-year change 3-year change Capi.($)
+5.81%-7.17%-61.79%-89.61% 7.08M
+3.23%+2.25%+65.02%+116.66% 54.54B
+0.04%+5.05%+43.44%+36.75% 43.86B
+3.46%+6.92%-12.25%-16.21% 22.63B
+2.50%+6.61%-2.32%+384.69% 20.7B
-0.53%-0.27%+12.68%-37.07% 15.84B
+5.27%+1.87%+13.67%-38.00% 14.83B
+1.00%-0.26%+26.82%+176.90% 13.1B
-5.17%+4.13%+13.12% - 12.66B
-0.20%+6.19%+79.01%+103.89% 11.56B
Average +1.52%-1.43%+17.74%+70.89% 20.97B
Weighted average by Cap. +1.54%+0.18%+33.18%+91.03%

Financials

2026 *2027 *
Net sales - -
Net income -41.32M -35.64M -32.77M -30.84M -57.96M -3.9B -58.44M -388M -151M -1.91B -155M -152M -6.62B -55.23M -47.65M -43.81M -41.23M -77.48M -5.21B -78.13M -519M -202M -2.56B -207M -203M -8.85B
Net Debt - -
Logo NextCure, Inc.
NextCure, Inc. is a clinical-stage biopharmaceutical company that is focused on advancing medicines that treat cancer patients that do not respond to, or have disease progression on, current therapies, through the use of differentiated mechanisms of action, including antibody-drug conjugates (ADC). It focuses on advancing therapies that leverage its core strengths in understanding biological pathways and biomarkers, the interactions of cells, including in the tumor microenvironment, and the role each interaction plays in a biologic response. Its product candidate, LNCB74, is designed as a B7-H4 targeted ADC to kill tumors. Its clinical oncology programs include NC410 and NC525. NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of, and decoy protein for, LAIR-1 that is designed to block immune suppression mediated by LAIR-1. NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells.
Employees
40
Date Price Change Volume
17/06/26 2.074 $ +5.81% 138,481
16/06/26 1.960 $ -1.01% 192,662
15/06/26 1.980 $ -4.58% 141,500
12/06/26 2.075 $ -6.95% 215,588
11/06/26 2.230 $ 0.00% 136,274
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.960USD
Average target price
19.33USD
Spread / Average Target
+886.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NXTC Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!